Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma.
Adenocarcinoma
/ complications
Adult
Aged
Aged, 80 and over
Body Composition
Comorbidity
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Nutritional Status
Obesity
/ complications
Pancreatic Neoplasms
/ complications
Postoperative Complications
/ etiology
Prognosis
Retrospective Studies
Sarcopenia
/ complications
Tomography, X-Ray Computed
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
11
2018
accepted:
10
04
2019
entrez:
7
5
2019
pubmed:
7
5
2019
medline:
14
1
2020
Statut:
epublish
Résumé
Incidence and mortality of pancreatic ductal adenocarcinoma (PDAC) are on the rise. Sarcopenia and sarcopenic obesity have proven to be prognostic factors in different types of cancers. In the context of previous findings, we evaluated the impact of body composition in patients undergoing surgery in a national pancreatic center. Patient's body composition (n = 133) was analyzed on diagnostic CT scans and defined as follows: Skeletal muscle index ≤38.5 cm2/m2 (women), ≤52.4 cm2/m2 (men); obesity was classified as BMI ≥25kg/m2. Sarcopenia showed a negative impact on overall survival (OS; 14 vs. 20 months, p = 0.016). Sarcopenic patients suffering from obesity showed poorer OS compared to non-sarcopenic obese patients (14 vs. 23 months, p = 0.007). Both sarcopenia and sarcopenic obesity were associated with sex (p<0.001 and p = 0.006; males vs. females 20% vs. 38% and 12% vs. 38%, respectively); sarcopenia was further associated with neoadjuvant treatment (p = 0.025), tumor grade (p = 0.023), weight loss (p = 0.02) and nutritional depletion (albumin, p = 0.011) as well as low BMI (<25 kg/m2, p = 0.038). Sarcopenic obese patients showed higher incidence of major postoperative complications (p<0.001). In addition, sarcopenia proved as an independent prognostic factor for OS (p = 0.031) in the multivariable Cox Regression model. Patients with sarcopenia and sarcopenic obesity undergoing resection for PDAC have a significantly shorter overall survival and a higher complication rate. The assessment of body composition in these patients may provide a broader understanding of patients' individual condition and guide specific supportive strategies in patients at risk.
Sections du résumé
BACKGROUND
Incidence and mortality of pancreatic ductal adenocarcinoma (PDAC) are on the rise. Sarcopenia and sarcopenic obesity have proven to be prognostic factors in different types of cancers. In the context of previous findings, we evaluated the impact of body composition in patients undergoing surgery in a national pancreatic center.
METHODS
Patient's body composition (n = 133) was analyzed on diagnostic CT scans and defined as follows: Skeletal muscle index ≤38.5 cm2/m2 (women), ≤52.4 cm2/m2 (men); obesity was classified as BMI ≥25kg/m2.
RESULTS
Sarcopenia showed a negative impact on overall survival (OS; 14 vs. 20 months, p = 0.016). Sarcopenic patients suffering from obesity showed poorer OS compared to non-sarcopenic obese patients (14 vs. 23 months, p = 0.007). Both sarcopenia and sarcopenic obesity were associated with sex (p<0.001 and p = 0.006; males vs. females 20% vs. 38% and 12% vs. 38%, respectively); sarcopenia was further associated with neoadjuvant treatment (p = 0.025), tumor grade (p = 0.023), weight loss (p = 0.02) and nutritional depletion (albumin, p = 0.011) as well as low BMI (<25 kg/m2, p = 0.038). Sarcopenic obese patients showed higher incidence of major postoperative complications (p<0.001). In addition, sarcopenia proved as an independent prognostic factor for OS (p = 0.031) in the multivariable Cox Regression model.
CONCLUSION
Patients with sarcopenia and sarcopenic obesity undergoing resection for PDAC have a significantly shorter overall survival and a higher complication rate. The assessment of body composition in these patients may provide a broader understanding of patients' individual condition and guide specific supportive strategies in patients at risk.
Identifiants
pubmed: 31059520
doi: 10.1371/journal.pone.0215915
pii: PONE-D-18-32473
pmc: PMC6502449
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0215915Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pancreatology. 2015 Jan-Feb;15(1):19-24
pubmed: 25524484
J Gastrointest Surg. 2012 Aug;16(8):1478-86
pubmed: 22692586
Int J Surg. 2017 Mar;39:45-51
pubmed: 28110029
Am J Clin Nutr. 2013 Oct;98(4):1012-9
pubmed: 23966429
Ann Oncol. 2014 Aug;25(8):1650-6
pubmed: 24759568
J Appl Physiol (1985). 1998 Jul;85(1):115-22
pubmed: 9655763
BMJ Support Palliat Care. 2018 Sep;8(3):258-265
pubmed: 29440149
World J Gastroenterol. 2016 Jul 28;22(28):6424-33
pubmed: 27605878
JAMA Oncol. 2017 Dec 1;3(12):e172319
pubmed: 28796857
J Surg Oncol. 2015 Oct;112(5):503-9
pubmed: 26310812
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Br J Surg. 2016 Mar;103(4):434-42
pubmed: 26780231
Clin Nutr. 2016 Oct;35(5):1103-9
pubmed: 26411749
J Nutr Health Aging. 2018;22(7):766-773
pubmed: 30080217
J Pain Symptom Manage. 2012 Aug;44(2):181-91
pubmed: 22695045
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):778-788
pubmed: 28614627
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):317-326
pubmed: 27897432
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Br J Cancer. 1997;75(1):106-9
pubmed: 9000606
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Arch Intern Med. 2000 Mar 27;160(6):861-8
pubmed: 10737287
J Cachexia Sarcopenia Muscle. 2017 Feb;8(1):25-39
pubmed: 27897391
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
HPB (Oxford). 2010 Jun;12(5):323-4
pubmed: 20590907
Surgery. 2015 Jun;157(6):1088-98
pubmed: 25799468
J Gastrointest Surg. 2008 Jul;12(7):1193-201
pubmed: 18347879
Ann Hematol. 2015 Dec;94(12):2043-53
pubmed: 26385388
Br J Surg. 2015 Nov;102(12):1448-58
pubmed: 26375617
Clin Nutr. 2012 Aug;31(4):499-505
pubmed: 22296872
HPB (Oxford). 2010 Jun;12(5):325-33
pubmed: 20590908
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
Nutrition. 2016 Nov-Dec;32(11-12):1231-7
pubmed: 27261062
BMJ Open Gastroenterol. 2018 Feb 7;5(1):e000194
pubmed: 29527315
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):285-297
pubmed: 27897414
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
J Am Geriatr Soc. 2017 Sep;65(9):1988-1995
pubmed: 28653345
J Gastrointest Surg. 2016 Sep;20(9):1586-94
pubmed: 27126054
Curr Opin Clin Nutr Metab Care. 2001 Nov;4(6):503-8
pubmed: 11706284
J Surg Oncol. 2017 Nov;116(6):658-664
pubmed: 28628722
Ann Surg Oncol. 2015 Jul;22(7):2416-23
pubmed: 25519927
Nutr Cancer. 2013;65(6):827-33
pubmed: 23909726
Surgery. 2012 Sep;152(3 Suppl 1):S81-8
pubmed: 22770957
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):295-305
pubmed: 29271097
World J Gastroenterol. 2014 Jul 28;20(28):9361-73
pubmed: 25071331
BMC Geriatr. 2017 Aug 21;17(1):188
pubmed: 28826406
Ann Surg Oncol. 2017 Nov;24(12):3732-3740
pubmed: 28871520
Int J Surg. 2018 Nov;59:19-26
pubmed: 30266663
J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):73-6
pubmed: 22565649
Int J Obes Relat Metab Disord. 1996 Jun;20(6):570-3
pubmed: 8782734
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):315-325
pubmed: 29318756
Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9
pubmed: 29506228
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Front Physiol. 2014 Mar 03;5:88
pubmed: 24624094
Nutr J. 2010 Dec 22;9:69
pubmed: 21176210
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
World J Gastrointest Surg. 2016 Jan 27;8(1):27-40
pubmed: 26843911
Clin Cancer Res. 2009 Nov 15;15(22):6973-9
pubmed: 19887488
Ann Surg. 2017 Nov;266(5):822-830
pubmed: 28796017
Med Sci Sports Exerc. 2014 Apr;46(4):664-70
pubmed: 24042308
PLoS One. 2015 Oct 05;10(10):e0139749
pubmed: 26437072